From a portfolio rotation perspective, AQST stock forecast stands to benefit as investors move capital from mega-cap tech into high-growth biotech names during Q1 rebalancing. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. If approved, Anaphylm would become the first and only non-invasive, orally delivered epinephrine product to be approved by the FDA for the treatment of severe allergic reactions, including anaphylaxis. A potential approval would offer a needle-free epinephrine option for people who stand at severe allergy risk. Market chatter driving AQST stock forecast sentiment points to a stronger valuation case if the company secures European distribution agreements by year-end, unlocking new revenue streams.
